PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-cell Lymphoma

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2022 Apr 13

PMID 35415904

Authors

Huilai Zhang

Yaxiao Lu

Tingting Zhang

Qingpei Guan

Xiaoxuan Wang

Yixian Guo

Lanfang Li

Lihua Qiu

Zhengzi Qian

Shiyong Zhou

Wenchen Gong

Bin Meng

Xiubao Ren

Xianhuo Wang

Affiliations

Soon will be listed here.

Citing Articles

Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma.

Hattori K, Makishima K, Suma S, Abe Y, Suehara Y, Sakamoto T EJHaem. 2024; 5(6):1201-1214.

PMID: 39691244 PMC: 11647707. DOI: 10.1002/jha2.1046.

High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.

Lone W, Bouska A, Herek T, Amador C, Song J, Xu A Am J Hematol. 2024; 100(1):10-22.

PMID: 39548807 PMC: 11625982. DOI: 10.1002/ajh.27513.

Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements.

Monika F, Sabri A, Cantu D, Vail E, Siref A J Hematop. 2024; 17(3):155-161.

PMID: 38914869 PMC: 11324669. DOI: 10.1007/s12308-024-00593-8.

Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.

Berendsen M, van Bladel D, Hesius E, Berganza Irusquieta C, Rijntjes J, Spriel A Hemasphere. 2023; 7(11):e976.

PMID: 37928625 PMC: 10621888. DOI: 10.1097/HS9.0000000000000976.

Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).

Kim P, Nejati R, Lu P, Thakkar D, Mackrides N, Dupoux V Cold Spring Harb Mol Case Stud. 2023; 9(4).

PMID: 37730436 PMC: 10815299. DOI: 10.1101/mcs.a006283.

References

Xu-Monette Z, Wu L, Visco C, Tai Y, Tzankov A, Liu W . Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012; 120(19):3986-96. PMC: 3496956. DOI: 10.1182/blood-2012-05-433334. View

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti R, Kuppers R . Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001; 412(6844):341-6. DOI: 10.1038/35085588. View

Miao Y, Medeiros L, Li Y, Li J, Young K . Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019; 16(10):634-652. DOI: 10.1038/s41571-019-0225-1. View

Fernandez-Rodriguez C, Bellosillo B, Garcia-Garcia M, Sanchez-Gonzalez B, Gimeno E, Vela M . MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014; 28(10):2104-6. DOI: 10.1038/leu.2014.184. View

De Smedt R, Morscio J, Reunes L, Roels J, Bardelli V, Lintermans B . Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood. 2020; 135(19):1685-1695. DOI: 10.1182/blood.2019003880. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Szydlowski M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, Hoser G, Wasilewska D . Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017; 130(12):1418-1429. DOI: 10.1182/blood-2017-01-760702. View

Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E . PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016; 22(11):1303-1313. PMC: 5552044. DOI: 10.1038/nm.4198. View

10.

Trinh D, Scott D, Morin R, Mendez-Lago M, An J, Jones S . Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013; 121(18):3666-74. PMC: 3643765. DOI: 10.1182/blood-2013-01-479865. View